Miglustat Accord (Miglustat)

Miglustat is a substrate reduction therapy that targets the accumulation of glycosphingolipids in lysosomal storage disorders.

• Niemann‑Pick disease type C: slows neurological decline and improves survival outcomes.
• Gaucher disease type 1: reduces spleen and liver volume and improves hematologic parameters.

• Miglustat inhibits the enzyme glucosylceramide synthase, the first step in glycosphingolipid biosynthesis. By blocking this pathway, the drug reduces the production of glucosylceramide and downstream glycosphingolipids, decreasing substrate accumulation in cells affected by lysosomal storage diseases.

Miglustat may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

• Diarrhea: frequent loose stools.
• Nausea: feeling of stomach upset.
• Flatulence: increased intestinal gas.
• Weight loss: unintended reduction in body weight.
• Tremor: mild shaking of hands or limbs.
• Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects

• Pancreatitis: inflammation of the pancreas requiring immediate medical attention.
• Severe hypersensitivity: rash, swelling, or difficulty breathing.
• Liver enzyme elevation: significant increase in hepatic transaminases.
• Depression or mood changes: new or worsening psychiatric symptoms.

Before initiating therapy, clinicians should assess patient-specific factors and monitor for potential complications.

• Liver function monitoring: check transaminases regularly.
• Blood glucose assessment: monitor for hypoglycemia, especially in diabetic patients.
• Gastrointestinal tolerance: evaluate for persistent diarrhea or weight loss.
• Renal impairment: adjust use in patients with reduced kidney function.
• Hypersensitivity screening: avoid in individuals with known allergy to miglustat.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Miglustat can interact with several drug classes, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase miglustat plasma levels.
• Concomitant antidiabetic agents: heightened risk of hypoglycemia.
• Other substrate reduction therapies: additive toxicity risk.

Moderate Interactions (Monitor Closely)

• Moderate CYP inducers (e.g., rifampicin): may reduce miglustat effectiveness.
• Antacids containing aluminum or magnesium: can affect gastrointestinal absorption.
• Warfarin: may require INR monitoring due to potential interaction.